ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
핵황달 치료 시장 규모는 향후 몇 년 동안 안정적인 성장세를 보일 것으로 예상되며, 2029년에는 2.4%의 연평균 성장률(CAGR)로 33억 7,000만 달러에 달할 것으로 예상됩니다. 예측 기간의 성장은 지속적인 의학 교육 프로그램, 세계 보건 정책 및 이니셔티브, 환자 옹호 및 지원 단체, 소아과 연구 국제 협력, 신생아 보건을 위한 정부 보조금 등에 기인하는 것으로 보입니다. 예측 기간의 주요 동향으로는 신생아 황달 모니터링 기술의 발전, 향상된 기능의 광선 요법 장비 도입, 빌리루빈 감소 약물 개발, 재택 광선 요법 솔루션의 중요성, 빌리루빈 노모그램 및 가이드라인의 도입, 원격 모니터링을 위한 원격의료의 통합 등이 있습니다.
신생아 황달의 유병률 증가는 핵황달 치료 시장의 성장을 촉진할 것으로 예상됩니다. 신생아 황달은 일반적으로 신생아에서 관찰되는 양성 질환으로 피부와 눈의 황변을 특징으로 하는 질환입니다. 신생아 황달의 경우 증상 관리 및 지지요법을 제공하기 위해 케르니클투스 치료가 종종 적용됩니다. 이 치료는 아기의 혈액을 빌리루빈 농도가 낮은 혈액으로 대체하여 아이의 삶의 질을 향상시킵니다. 예를 들어, 2023년 10월 미국 국립의학도서관은 정상 출생아의 약 60%, 조산아의 약 80%가 생후 1주일 이내에 황달이 발생하며, 모유 수유아의 약 10%가 1달이 지나도 황달을 보입니다고 보고했습니다. 이처럼 신생아 황달의 광범위한 발생은 케르니클투스 치료제 시장을 견인할 것으로 예상됩니다.
헬스케어 지출의 증가는 핵황달 치료 시장의 성장에 박차를 가하고 있습니다. 이러한 지출은 의료 서비스, 프로그램, 인프라의 확장 및 강화에 따른 비용 상승에 대응하기 위해 의료 부문에서 이루어지는 추가 투자를 의미합니다. 이러한 지출은 환아 및 소아 환자의 치료의 질과 접근성을 향상시켜 치료 결과의 개선과 삶의 질 향상으로 이어져 케르니쿨루스 치료에 큰 영향을 미칠 수 있습니다. 예를 들어, 2023년 11월 캐나다 의료정보연구소(Canadian Institute for Health Information)는 2023년 캐나다의 총 의료비는 3,440억 달러(1인당 8,740달러)에 달하고, 전년도 성장률 1.5%에서 2.8% 증가할 것으로 보고하여 의료 투자의 강력한 부활을 시사했습니다. 그 결과, 헬스케어 지출 증가가 케르니클투스 치료 시장 성장의 원동력이 되고 있습니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 동향과 전략
제4장 시장 - 금리, 인플레이션, 지정학, 코로나, 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제5장 세계의 성장 분석과 전략 분석 프레임워크
세계 핵황달 치료 PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인, 억제요인)
최종 이용 산업 분석
세계의 핵황달 치료 시장 : 성장률 분석
세계의 핵황달 치료 시장 실적 : 규모와 성장, 2019-2024
세계의 핵황달 치료 시장 예측 : 규모와 성장, 2024-2029, 2034F
세계 핵황달 치료 전체 시장(TAM)
제6장 시장 세분화
세계의 핵황달 치료 시장 : 치료별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
광선요법
정맥내 면역글로불린(IVIG)
수혈
약
기타 치료법
세계의 핵황달 치료 시장 : 증상별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
황달
비정상인 안구 운동
구토
열
영양 불량
무호흡
초조
발작
졸음
기타 증상
세계의 핵황달 치료 시장 : 투여량별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
주사
솔루션
기타 투여량
세계의 핵황달 치료 시장 : 최종사용자별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
클리닉
병원
기타 최종사용자
세계의 핵황달 치료 시장, 광선요법 종류별 하위 세분화, 실적과 예측, 2019-2024, 2024-2029F, 2034F
기존 광선요법
섬유 옵틱 광선요법
LED 광선요법
세계의 핵황달 치료 시장, 정맥내 면역글로불린(IVIG) 하위 세분화, 유형별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
표준적 IVIG 요법
고용량 IVIG 요법
세계의 핵황달 치료 시장, 수혈 종류별 하위 세분화, 실적과 예측, 2019-2024, 2024-2029F, 2034F
교환 수혈
단순 수혈
세계의 핵황달 치료 시장, 의약품 하위 세분화, 유형별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
빌리루빈 저하제
항산화물질
신경보호제
세계의 핵황달 치료 시장, 기타 치료법 하위 세분화, 유형별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
지지요법
영양 서포트
보조 요법
제7장 지역별·국가별 분석
세계의 핵황달 치료 시장 : 지역별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
세계의 핵황달 치료 시장 : 국가별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
제8장 아시아태평양 시장
제9장 중국 시장
제10장 인도 시장
제11장 일본 시장
제12장 호주 시장
제13장 인도네시아 시장
제14장 한국 시장
제15장 서유럽 시장
제16장 영국 시장
제17장 독일 시장
제18장 프랑스 시장
제19장 이탈리아 시장
제20장 스페인 시장
제21장 동유럽 시장
제22장 러시아 시장
제23장 북미 시장
제24장 미국 시장
제25장 캐나다 시장
제26장 남미 시장
제27장 브라질 시장
제28장 중동 시장
제29장 아프리카 시장
제30장 경쟁 구도와 기업 개요
핵황달 치료 시장 : 경쟁 구도
핵황달 치료 시장 : 기업 개요
Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
F. Hoffmann-La Roche Ltd Overview, Products and Services, Strategy and Financial Analysis
Merck and Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
Bayer AG Overview, Products and Services, Strategy and Financial Analysis
제31장 기타 주요 기업과 혁신적 기업
Novartis AG
AstraZeneca plc.
Abbott Laboratories
Sanofi SA
GlaxoSmithKline plc
Takeda Pharmaceutical Company Limited
Johnson and Johnson Private Limited
Baxter International Inc.
Grifols S.A
Sun Pharmaceutical Industries Ltd.
Dr. Reddy's Laboratories Ltd.
Alembic Pharmaceuticals Limited
Lupin Pharmaceuticals Inc.
CSL Limited
Glenmark Pharmaceuticals Ltd.
제32장 세계의 시장 경쟁 벤치마킹과 대시보드
제33장 주요 인수합병
제34장 최근의 시장 동향
제35장 시장 잠재력이 높은 국가, 부문, 전략
핵황달 치료 시장 2029 : 새로운 기회를 제공하는 국가
핵황달 치료 시장 2029 : 새로운 기회를 제공하는 부문
핵황달 치료 시장 2029 : 성장 전략
시장 동향에 기반한 전략
경쟁 전략
제36장 부록
ksm
영문 목차
영문목차
Kernicterus is an infrequent neurological condition that may manifest in newborns experiencing severe jaundice, marked by elevated levels of bilirubin in the bloodstream. Treatment for kernicterus encompasses medical interventions, therapies, and supportive care, primarily administered to infants and children, with the goal of addressing symptoms, complications, and long-term effects, ultimately enhancing the affected individuals' quality of life.
The primary modalities for treating kernicterus include phototherapy, intravenous immunoglobulins (IVIG), blood transfusion, medication, and other supportive measures. Phototherapy involves the application of light, typically specialized lights or lamps, as a medical intervention. This method is employed to address a range of symptoms associated with kernicterus, such as jaundice, unusual eye movements, vomiting, fever, poor feeding, apnea, irritability, seizures, sleepiness, and others. Dosage administration may take various forms, including injections, solutions, and other delivery methods. The end users of these treatments include clinics, hospitals, and other healthcare facilities.
The kernicterus treatment market research report is one of a series of new reports from The Business Research Company that provides kernicterus treatment market statistics, including kernicterus treatment industry global market size, regional shares, competitors with a kernicterus treatment market share, detailed kernicterus treatment market segments, market trends and opportunities, and any further data you may need to thrive in the kernicterus treatment industry. This kernicterus treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The kernicterus treatment market size has grown steadily in recent years. It will grow from $2.98 billion in 2024 to $3.06 billion in 2025 at a compound annual growth rate (CAGR) of 3.0%. The growth in the historic period can be attributed to improvements in neonatal care practices, increased awareness among healthcare professionals, government initiatives for maternal and child health, research funding and clinical trials, collaborations in medical research.
The kernicterus treatment market size is expected to see steady growth in the next few years. It will grow to $3.37 billion in 2029 at a compound annual growth rate (CAGR) of 2.4%. The growth in the forecast period can be attributed to continuous medical education programs, global health policies and initiatives, patient advocacy and support groups, international collaboration in pediatric research, government funding for neonatal health. Major trends in the forecast period include advancements in neonatal jaundice monitoring technologies, introduction of phototherapy devices with enhanced features, development of bilirubin-reducing medications, focus on home-based phototherapy solutions, implementation of bilirubin nomograms and guidelines, integration of telehealth for remote monitoring.
The rising prevalence of neonatal jaundice is expected to drive the growth of the kernicterus treatment market. Neonatal jaundice, commonly observed in newborns, is typically a benign condition marked by yellowing of the skin and eyes. Kernicterus treatment is often applied in cases of neonatal jaundice to manage symptoms and provide supportive care. This treatment involves exchanging the baby's blood with blood containing lower bilirubin levels, which enhances the child's quality of life. For instance, in October 2023, the U.S.-based National Library of Medicine reported that approximately 60% of term infants and 80% of preterm infants develop jaundice within their first week, with about 10% of breastfed infants still showing jaundice at one month. Thus, the widespread occurrence of neonatal jaundice is anticipated to boost the kernicterus treatment market.
Increasing healthcare spending is fueling the growth of the kernicterus treatment market. This type of spending refers to additional investments made in the healthcare sector to address the rising costs associated with expanding or enhancing healthcare services, programs, or infrastructure. Such spending significantly impacts kernicterus treatment by improving the quality and accessibility of care for affected infants and children, leading to better treatment outcomes and an improved quality of life. For example, in November 2023, the Canadian Institute for Health Information reported that total healthcare spending in Canada is expected to reach $344 billion in 2023, or $8,740 per person, marking a 2.8% increase from the prior year's 1.5% growth rate, signaling a strong resurgence in healthcare investment. Consequently, increased healthcare spending is a driving force behind the growth of the kernicterus treatment market.
Key organizations in the cornea treatment market are increasingly focusing on partnerships to expand their reach and strengthen their competitive position. For example, in July 2024, the UCL Department of Medical Physics and Biomedical Engineering, a UK-based institution known for its contributions to medical physics and biomedical engineering research and education, collaborated with UCL Hospitals, a UK-based healthcare provider, to launch NeoSCB. This smartphone application detects severe jaundice in newborns by analyzing images of the sclera (the white part of the eye), offering a non-invasive screening method. The app is particularly valuable in resource-limited settings where traditional jaundice screening devices are expensive. By measuring the yellowness of the sclera, the app correlates this data with bilirubin levels in the blood, achieving a high accuracy rate by successfully identifying 74 out of 79 infants with severe jaundice. Its performance is comparable to conventional methods, such as transcutaneous bilirubinometers, which measure bilirubin through the skin.
In March 2024, Intermountain Health, a US-based nonprofit healthcare system, formed a partnership with Picterus AS to enhance early jaundice detection for newborns. This collaboration aims to improve health outcomes by offering a non-invasive and accessible screening method. Picterus AS, a healthcare technology company based in Norway, specializes in developing technology for screening and monitoring neonatal jaundice.
Major companies operating in the kernicterus treatment market report are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck and Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, AstraZeneca plc., Abbott Laboratories, Sanofi SA, GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Johnson and Johnson Private Limited, Baxter International Inc., Grifols S.A, Sun Pharmaceutical Industries Ltd., Dr. Reddy's Laboratories Ltd., Alembic Pharmaceuticals Limited, Lupin Pharmaceuticals Inc., CSL Limited, Glenmark Pharmaceuticals Ltd., Cipla Inc., Torrent Pharmaceuticals Ltd., Octapharma Brasil Ltda, Kedrion S.p.A, Biotest AG, Wockhardt Ltd., Mylan N.V., Cadila Healthcare Ltd., Teva Pharmaceutical Industries Ltd., China Biologic Products Holdings Inc.
North America was the largest region in the kernicterus treatment market in 2024. The regions covered in the kernicterus treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the kernicterus treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The kernicterus treatment market consists of revenues earned by entities by provide kernicterus treatment services such as diagnostic tests, neurological management, medical evaluation and monitoring and exchange transfusion services. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Kernicterus Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on kernicterus treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for kernicterus treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The kernicterus treatment market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:1) By Treatment: Phototherapy; Intravenous Immunoglobulins (IVIG); Blood Transfusion; Medication; Other Treatments
2) By Symptoms: Jaundice; Unusual Eye Movements; Vomiting; Fever; Poor Feeding; Apnoea; Irritability; Seizures; Sleepiness; Other Symptoms
3) By Dosage: Injection; Solution; Other Dosages
4) By End-Users: Clinic; Hospital; Other End-Users
Subsegments:
1) By Phototherapy: Conventional Phototherapy; Fiberoptic Phototherapy; LED Phototherapy
2) By Intravenous Immunoglobulins (IVIG): Standard IVIG Therapy; High-Dose IVIG Therapy
3) By Blood Transfusion: Exchange Transfusion; Simple Transfusion
4) By Medication: Bilirubin-Lowering Agents; Antioxidants; Neuroprotective Agents
5) By Other Treatments: Supportive Care; Nutritional Support; Adjunct Therapies
Companies Mentioned: Pfizer Inc.; F. Hoffmann-La Roche Ltd; Merck and Co. Inc.; AbbVie Inc.; Bayer AG
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery format: PDF, Word and Excel Data Dashboard.
Table of Contents
1. Executive Summary
2. Kernicterus Treatment Market Characteristics
3. Kernicterus Treatment Market Trends And Strategies
4. Kernicterus Treatment Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market
5. Global Kernicterus Treatment Growth Analysis And Strategic Analysis Framework
5.1. Global Kernicterus Treatment PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Kernicterus Treatment Market Growth Rate Analysis
5.4. Global Kernicterus Treatment Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Kernicterus Treatment Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Kernicterus Treatment Total Addressable Market (TAM)
6. Kernicterus Treatment Market Segmentation
6.1. Global Kernicterus Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Phototherapy
Intravenous Immunoglobulins (IVIG)
Blood Transfusion
Medication
Other Treatments
6.2. Global Kernicterus Treatment Market, Segmentation By Symptoms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Jaundice
Unusual Eye Movements
Vomiting
Fever
Poor Feeding
Apnoea
Irritability
Seizures
Sleepiness
Other Symptoms
6.3. Global Kernicterus Treatment Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Injection
Solution
Other Dosages
6.4. Global Kernicterus Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Clinic
Hospital
Other End-Users
6.5. Global Kernicterus Treatment Market, Sub-Segmentation Of Phototherapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Conventional Phototherapy
Fiberoptic Phototherapy
LED Phototherapy
6.6. Global Kernicterus Treatment Market, Sub-Segmentation Of Intravenous Immunoglobulins (IVIG), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Standard IVIG Therapy
High-Dose IVIG Therapy
6.7. Global Kernicterus Treatment Market, Sub-Segmentation Of Blood Transfusion, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Exchange Transfusion
Simple Transfusion
6.8. Global Kernicterus Treatment Market, Sub-Segmentation Of Medication, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Bilirubin-Lowering Agents
Antioxidants
Neuroprotective Agents
6.9. Global Kernicterus Treatment Market, Sub-Segmentation Of Other Treatments, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Supportive Care
Nutritional Support
Adjunct Therapies
7. Kernicterus Treatment Market Regional And Country Analysis
7.1. Global Kernicterus Treatment Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Kernicterus Treatment Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
